Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9206133 | 0.87 | GFER (0.36) | TAAR1FFAR1MAOB | |
| SCHEMBL3247875 | 0.86 | TAAR1 (0.46) | TAAR1FFAR1MAOBIDO1LOXL2 | |
| SCHEMBL5538115 | 0.85 | TAAR1 (0.45) | TAAR1FFAR1MAOBAOC3 | |
| SCHEMBL5539540 | 0.83 | TAAR1 (0.43) | TAAR1FFAR1MAOB | |
| SCHEMBL440374 | 0.76 | TAAR1 (0.50) | TAAR1MAOBIDO1AOC3DAO | |
| SCHEMBL8439000 | 0.76 | HRH3 (0.46) | TAAR1LOXL2 | |
| SCHEMBL692408 | 0.76 | GFER (0.59) | MAOBLOXL2 | |
| SCHEMBL910881 | 0.76 | CA2 (0.47) | — | |
| SCHEMBL4847285 | 0.76 | DAO (0.40) | TAAR1IDO1DAO | |
| SCHEMBL98012 | 0.76 | TAAR1 (0.50) | TAAR1FFAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-7732412-B2 | Methods of treatment using novel LHRH antagonists having improved solubility properties | ZENTARIS GMBH (DE) | 2010-06-08 | — | — | US | claimed |
| EP-1830818-B1 | PROCESS FOR THE MANUFACTURE OF STERILE SUSPENSIONS OR LYOPHILISATES OF LOW-SOLUBLE BASIC PEPTIDE COMPLEXES, PHARMACEUTICAL FORMULATIONS COMPRISING THESE COMPLEXES AND THEIR USE AS MEDICAMENT | AETERNA ZENTARIS GMBH (DE) | 2010-04-07 | — | — | EP | claimed |
| US-20060281685-A1 | METHODS OF TREATMENT USING NOVEL LHRH ANTAGONISTS HAVING IMPROVED SOLUBILITY PROPERTIES | ZENTARIS GMBH (DE) | 2006-12-14 | — | — | US | claimed |
| US-7148195-B2 | LHRH antagonists having improved solubility properties | ZENTARIS GMBH (DE) | 2006-12-12 | — | — | US | claimed |
| US-20060135405-A1 | Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments | ZENTARIS GMBH (DE) | 2006-06-22 | — | — | US | claimed |
| US-20050159335-A1 | Pharmaceutical administration form for peptides, process for its preparation, and use | AETERNA ZENTARIS GMBH (DE) | 2005-07-21 | — | — | US | claimed |
| CN-1185251-C | Novel LHRH-antagonists with improved solubility characteristics | ZANTARIS AG (DE) | 2005-01-19 | — | — | CN | claimed |
| US-20040266695-A1 | Novel LHRH antagonists having improved solubility properties | BERND MICHAEL | 2004-12-30 | — | — | US | claimed |
| WO-1995024424-A1 | CYCLIC PEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1994025046-A1 | METHOD OF COMBATING ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRAL INFECTIONS | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1994-11-10 | — | — | WO | claimed |
| WO-1993018056-A1 | ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-16 | — | — | WO | claimed |
| EP-0560267-A1 | Isosteric antiherpes peptide derivatives | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1993-09-15 | — | — | EP | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0480918-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135405-A1 | Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments | VIP, NASP, SPCS2 | TAAR1 4469/4885FFAR1 1690/4885MAOB 4666/4885 |
| US-20060281685-A1 | METHODS OF TREATMENT USING NOVEL LHRH ANTAGONISTS HAVING IMPROVED SOLUBILITY PROPERTIES | GNRHR, PRLHR, FSHR | TAAR1 3388/4885FFAR1 476/4885MAOB 2247/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | TAAR1 4623/4885FFAR1 1287/4885MAOB 1282/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | TAAR1 4623/4885FFAR1 1287/4885MAOB 1282/4885 |
| US-20040266695-A1 | Novel LHRH antagonists having improved solubility properties | LHCGR, GNRHR, PRLHR | TAAR1 2099/4885FFAR1 415/4885MAOB 4352/4885 |
| US-20050159335-A1 | Pharmaceutical administration form for peptides, process for its preparation, and use | LHCGR, GNRHR, GHRHR | TAAR1 4149/4885FFAR1 241/4885MAOB 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.